Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty

Y. Y. Tseng, C. H. Su, T. N. Lui, Y. S. Yeh, S. H. Yeh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Summary Most post-vertebroplasty new-onset adjacent vertebral compression fractures (VCFs) occur within 2- 3 months, and antiresorptive agents do not significantly reduce the risk of their occurrence. In opposite mechanism, teriparatide directly stimulates bone formation and improves bone strength and quality faster. The therapeutic effect of teriparatide is better than that of vertebroplasty combined with an antiresorptive treatment and is a potentially useful therapy for new-onset adjacent VCFs after vertebroplasty. Introduction Following vertebroplasty, patients are at increased risk of new-onset adjacent-level VCFs. The therapeutic effect of antiresorptive agents is too slow, and they are associated with the risk of new VCFs. Teriparatide markedly increases bone formation and strength and reduces the incidence of new-onset VCFs. This prospective cohort study compared the therapeutic effects of teriparatide with those of combined vertebroplasty and an anti-resorber for treating new-onset adjacent VCFs after vertebroplasty. Methods Fifty patients with adjacent VCFs were randomly assigned to two groups: teriparatide only (group A) and additional vertebroplasty combined with an antiresorptive agent (group B). Relevant clinical data of the two groups were prospectively compared. Results The 22 patients in group A were at higher risk of new VCFs than those in group B (22 patients); they were older and had more pre-existing fractures (p

Original languageEnglish
Pages (from-to)1613-1622
Number of pages10
JournalOsteoporosis International
Volume23
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Teriparatide
Bone Density Conservation Agents
Vertebroplasty
Compression Fractures
Therapeutic Uses
Therapeutics
Osteogenesis
Cohort Studies
Prospective Studies
Bone and Bones

Keywords

  • Adjacent vertebral fracture
  • Antiresorptive agent
  • Teriparatide .Vertebral compression fracture
  • Vertebroplasty

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

@article{3057546b915342c9b46bd1fbf6e20fed,
title = "Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty",
abstract = "Summary Most post-vertebroplasty new-onset adjacent vertebral compression fractures (VCFs) occur within 2- 3 months, and antiresorptive agents do not significantly reduce the risk of their occurrence. In opposite mechanism, teriparatide directly stimulates bone formation and improves bone strength and quality faster. The therapeutic effect of teriparatide is better than that of vertebroplasty combined with an antiresorptive treatment and is a potentially useful therapy for new-onset adjacent VCFs after vertebroplasty. Introduction Following vertebroplasty, patients are at increased risk of new-onset adjacent-level VCFs. The therapeutic effect of antiresorptive agents is too slow, and they are associated with the risk of new VCFs. Teriparatide markedly increases bone formation and strength and reduces the incidence of new-onset VCFs. This prospective cohort study compared the therapeutic effects of teriparatide with those of combined vertebroplasty and an anti-resorber for treating new-onset adjacent VCFs after vertebroplasty. Methods Fifty patients with adjacent VCFs were randomly assigned to two groups: teriparatide only (group A) and additional vertebroplasty combined with an antiresorptive agent (group B). Relevant clinical data of the two groups were prospectively compared. Results The 22 patients in group A were at higher risk of new VCFs than those in group B (22 patients); they were older and had more pre-existing fractures (p",
keywords = "Adjacent vertebral fracture, Antiresorptive agent, Teriparatide .Vertebral compression fracture, Vertebroplasty",
author = "Tseng, {Y. Y.} and Su, {C. H.} and Lui, {T. N.} and Yeh, {Y. S.} and Yeh, {S. H.}",
year = "2012",
month = "5",
doi = "10.1007/s00198-011-1730-y",
language = "English",
volume = "23",
pages = "1613--1622",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "5",

}

TY - JOUR

T1 - Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty

AU - Tseng, Y. Y.

AU - Su, C. H.

AU - Lui, T. N.

AU - Yeh, Y. S.

AU - Yeh, S. H.

PY - 2012/5

Y1 - 2012/5

N2 - Summary Most post-vertebroplasty new-onset adjacent vertebral compression fractures (VCFs) occur within 2- 3 months, and antiresorptive agents do not significantly reduce the risk of their occurrence. In opposite mechanism, teriparatide directly stimulates bone formation and improves bone strength and quality faster. The therapeutic effect of teriparatide is better than that of vertebroplasty combined with an antiresorptive treatment and is a potentially useful therapy for new-onset adjacent VCFs after vertebroplasty. Introduction Following vertebroplasty, patients are at increased risk of new-onset adjacent-level VCFs. The therapeutic effect of antiresorptive agents is too slow, and they are associated with the risk of new VCFs. Teriparatide markedly increases bone formation and strength and reduces the incidence of new-onset VCFs. This prospective cohort study compared the therapeutic effects of teriparatide with those of combined vertebroplasty and an anti-resorber for treating new-onset adjacent VCFs after vertebroplasty. Methods Fifty patients with adjacent VCFs were randomly assigned to two groups: teriparatide only (group A) and additional vertebroplasty combined with an antiresorptive agent (group B). Relevant clinical data of the two groups were prospectively compared. Results The 22 patients in group A were at higher risk of new VCFs than those in group B (22 patients); they were older and had more pre-existing fractures (p

AB - Summary Most post-vertebroplasty new-onset adjacent vertebral compression fractures (VCFs) occur within 2- 3 months, and antiresorptive agents do not significantly reduce the risk of their occurrence. In opposite mechanism, teriparatide directly stimulates bone formation and improves bone strength and quality faster. The therapeutic effect of teriparatide is better than that of vertebroplasty combined with an antiresorptive treatment and is a potentially useful therapy for new-onset adjacent VCFs after vertebroplasty. Introduction Following vertebroplasty, patients are at increased risk of new-onset adjacent-level VCFs. The therapeutic effect of antiresorptive agents is too slow, and they are associated with the risk of new VCFs. Teriparatide markedly increases bone formation and strength and reduces the incidence of new-onset VCFs. This prospective cohort study compared the therapeutic effects of teriparatide with those of combined vertebroplasty and an anti-resorber for treating new-onset adjacent VCFs after vertebroplasty. Methods Fifty patients with adjacent VCFs were randomly assigned to two groups: teriparatide only (group A) and additional vertebroplasty combined with an antiresorptive agent (group B). Relevant clinical data of the two groups were prospectively compared. Results The 22 patients in group A were at higher risk of new VCFs than those in group B (22 patients); they were older and had more pre-existing fractures (p

KW - Adjacent vertebral fracture

KW - Antiresorptive agent

KW - Teriparatide .Vertebral compression fracture

KW - Vertebroplasty

UR - http://www.scopus.com/inward/record.url?scp=84863626366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863626366&partnerID=8YFLogxK

U2 - 10.1007/s00198-011-1730-y

DO - 10.1007/s00198-011-1730-y

M3 - Article

VL - 23

SP - 1613

EP - 1622

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 5

ER -